CA2064075A1 - Human peripheral blood cells in an immunocompromised host - Google Patents
Human peripheral blood cells in an immunocompromised hostInfo
- Publication number
- CA2064075A1 CA2064075A1 CA002064075A CA2064075A CA2064075A1 CA 2064075 A1 CA2064075 A1 CA 2064075A1 CA 002064075 A CA002064075 A CA 002064075A CA 2064075 A CA2064075 A CA 2064075A CA 2064075 A1 CA2064075 A1 CA 2064075A1
- Authority
- CA
- Canada
- Prior art keywords
- host
- human
- bone marrow
- cells
- murine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 47
- 206010061598 Immunodeficiency Diseases 0.000 title claims abstract description 11
- 210000004976 peripheral blood cell Anatomy 0.000 title abstract description 10
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 30
- 230000001605 fetal effect Effects 0.000 claims abstract description 14
- 210000000601 blood cell Anatomy 0.000 claims abstract description 13
- 210000000988 bone and bone Anatomy 0.000 claims description 20
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 210000001165 lymph node Anatomy 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000002513 implantation Methods 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000001541 thymus gland Anatomy 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 230000009395 genetic defect Effects 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 241001529936 Murinae Species 0.000 claims 10
- 241000288906 Primates Species 0.000 claims 5
- 229940072221 immunoglobulins Drugs 0.000 claims 1
- 238000007801 sublethal irradiation Methods 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract description 9
- 210000005259 peripheral blood Anatomy 0.000 abstract description 5
- 239000011886 peripheral blood Substances 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 20
- 210000005260 human cell Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000002679 ablation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000000777 hematopoietic system Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002758 humerus Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- TVFDJXOCXUVLDH-RNFDNDRNSA-N cesium-137 Chemical compound [137Cs] TVFDJXOCXUVLDH-RNFDNDRNSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000055276 human IL3 Human genes 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 108700039855 mouse a Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000614 rib Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940048278 septra Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- External Artificial Organs (AREA)
Abstract
Human peripheral blood cell circulation is achieved in xenogeneic immunocompromised host with introduction of human fetal bone marrow into the host after irradiation of the host to substantially deplete the host of endogenous hematopoietic cells. The host remain viable for extended periods of time while demonstrating substantial levels of human blood cells in the peripheral blood.
Description
wo gl/18615 2~ 7S PCr/US91/03306 HUMAN PERIPHERAL BLOOD CELLS
IN AN IMMUNOCONPROMISED HOST
INTRODUCTION
Technical Field The field of this invention is the production of human hematopoietic cells.
Background The blood cell system comprising the diverse cells emanating from a single stem cell is essential to the survival and well being of mammals. The cells serve to carry oxygen, cleanse the body of debris, inhibit the proliferation of pathogens, monitor for neoplastic cells, and provide a wide variety of factors essential for their own and the growth of other cells. Recently, chimeric mice were developed, where human fetal tissue was introduced into CB-17 s d/scid mice to provide the chimeric SCID-hu mouse. The mice were shown to maintain for extended periods of time, human fetal lymph node and thymus and provide for peripheral blood cells, when supplied with a source of hematopoietic stem cells -from fetal liver. While in some instances, the maintenance of human peripheral blood cells could be extended for long periods of time, in all instances `~
.
the human cells were only a very small proportion of the total number of peripheral blood cells, `-. ,,, ~, . ...... .... . . ........ ........ ... .
frequently substantially fewer~than one percent.
Furthermore, the circulating cells in these animals were shown to be T Cells.
In many instances, it would be desirable to `
have a relatively high proportion of the peripheral blood cells as human cells and desirably have a . . . . .
WO91/186l5 PCT/US91/03306 2~ '5 -`
significant proportion of the total number of hematopoietic cells being human cells. Further, it would be desirable to have circulatory myelomonocytic cells and red blood cells, besides lymphoid cells.
For many applications, it would be of substantial advantage to have a high absolute number of human cells. These include the opportunity for immunization to obtain a strong immune response from the h~man cells, studies of various diseases and their effect on the various hematopoietic cells and studies of drugs against various diseases and their effect on the hematopoietic cells. There is, therefore, substantial interest in providing for ways in which a non-human mammal may be provided with human blood cells for testing, research, and as a source of blood cells of the various lineages.
. ~ ; , Relevant Literature EPA 0 322 240 describes the introduction of ~
human ~etal tissue in a C~-17 scid/scid mouse. See ~ ;
references cited therein.
` .
SUMMARY OF THE INVENTION
Xenogeneic bone marrow is introduced into an endogenous bone marrow depleted genetically ;~;~
immunocompromised mammalian host, where the bone ~ ;
marrow may be present as bone tissue or dispersed j:
bone marrow, particularly from a fetal source. The fetal bone tissue may be conveniently introduced into the peritoneal cavity or the bone marrow may be injectèd into the long bone of~the immunocompromised host.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
Non-human mammals, particularly small mammals .
WO91/18615 2~ ~. 5 PCT/US91/03306 under 25kg, are provided having human peripheral blood cells present as at least two percent (2%) of the total peripheral blood cells, preferably at least five percent (5%) of the total peripheral blood cells and more preferably at least about fifteen percent (15%). The enhanced level of human cells may be achieved by depletion of endogenous bone marrow, particularly stem cells, conveniently by irradiating the host with at least a sublethal dosage of radiation, generally being at least about 290 rad and varying with the size and nature of the host. The blood cells are then reconstituted with human bone marrow, conveniently as human bone or bone marrow cell suspensions, particularly from a ~ ;
fetal source. The human bone marrow source may be ~-introduced before and after ablation to enhance the survival rate of the host upon ablation, ; , particularly by irradiation.
Various immunocompromised hosts may be employed, where the host being immunocompromised is as a result of a natural mutation, breeding, transformation of embryonic cells to provide a transgenia mouse, or the like. Of particular interest are hosts which lack a functional lymphoid ;
~5 lineage. The lack of the immune system may be as a result of a lack of a particular organ, a genetic defect, such as an incompetent recombinase or regulatory gene regulating the expression of the recombinase, transport of sIg and T cell receptors to the surface, non-functional major - -histocompatibility antigensj or the like.- Of particular interest are CB-17 scid/scid mice and - mice derived therefrom which may have further enhanced immunodeficiency, e.g. lack of natural ~ ;
killer (NK) cells.
The host is irradiated or treated in any ' . ~ .
WO91/18615 2~ ~5 ~CT/US91/03306 convenient manner to substantially ablate the endogenous bone marrow. Conveniently, X-ir~adiation may be employed where the level of radiation will be selected to provide at least substantially complete ahlation of the hematopoietic cell system, while maintaining a reasonable, preferably a highl .
proportion of viable hosts. With each type of host, the particular level of irradiation may be selected by screening for the level of remaining viable hematopoietic cells for the efficiency of the ablation. Other techniques for bone marrow ablation -~
which may be employed by themselves or in combination include cytotoxic drugs, immunotoxins, antibodies to lymphokines and growth factors, ;:.
antibodies to natural killer cells, etc. The ;
selection of cytotoxic drugs would be based on their ability to clear quickly from the lymphatic and blood circulatory systems, so as to.rapidly be reduced to a non-cytotoxic level, prior to or .
shortly after the administration of the human bone :~.
marrow. :~
The human bone marrow will normally be fetal ;
bone marrow and may be employed as bone marrow slices, fragments, chunks, or the like, coming from ..
various parts of the fetus, such as the femur, tibia, humerus or rib. The longest dimensions of human bone will generally be in the size range of about 8mm to 2cm, where the bone may be fragmented :. :.
along.the long axis, usually in not more than about ,~
four parts. Usually, the total volume of fetal.bone .
which is;introduced into the-host will vary with the ~:
.- size of the host. For mice, the.volume will : generally be in the range of about ~Omm3 to 1,200mm3.
Alternatively, human fetal bone marrow cell ~ .
suspensions may be injected into long bones, such as the femur or tibia. Generally the volume of the - , ::: : -WO91/18615 ~ ~5 ` PCT/US91/03306 bone marrow suspension will be in the range of about lOml to 50ml for a mouse.
The age of the host will generally he at least neonatal and usually not more than about six months, more usually not more than three months. The particular age is not critical to this invention, but younger animals are more convenient to handle and are more economical.
The site of introduction of the fetal bone portions may be interperitoneal, subcutaneous, mammary fat pad, or other convenient site.
After introduction of the bone marrow, the host -is grown in accordance with conventional ways, `
feeding the host as appropriate, either with or without the presence of antibiotics in the feed.
Conveniently, about 0.2% to 1.2% of sulfamethoxazole/trimethoprim (Septra) may be provided in the feed. As appropriate, additional introductions of the human fetal bone marrow may be made, usually not more than about two additional explants, generally at four to twenty week intervals.
The hos~ may receive a variety of growth factors and cytokines, either native to the host or human. Interleukins, colony stimulating factors, hormones, or the like may be added, such as IL-l, IL-3, IL-6, and G-CSF. Generally, the amount of the additive will vary, depending upon the particular additive, the host, and the like. For example, in the case of IL-3 0.5 - 5 ~g/day may be administered.
In the subject host, it is found that the bone :- tissue shows variable cellularity from~lO to 80%.
In addition,-the human cells comprise a significant proportion of the blood cells in circulation in the peripheral blood. The cells may include members of the lymphoid, myelomonocytic and erythroid lineages.
WO91~1861S ~ ~ S PCT/US91/~3306 The cells may be detected by employing a wide varlety of antibodies which are commercially available for the detection of human markers on blood cells, such as CD-3, -4, -8, -l0, -13, -15, -19, -20, -33, -41, -45, -59, ~LA, or the like.
Conveniently, a blood sample may be taken and assayed employing a fluorescence activated cell ;~
sorter. Alternatively, the cells may be lysed and a Western blot employed. Other techniques which may ~ -find use for the quantitative determination of a ~ ~-particular cell type include the polymerase chain -~
reaction, gel electrophoresis, HPLC, or the like.
In addition to the bone marrow, other human organs may also be present, particularly thymus, lymph node, skin, liver, pancreas, tonsil, appendix, -epithelium, kidney, etc. One or more mesenteric or peripheral lymph nodes may be introduced. The various organs may be introduced conveniently in the kidney capsule, mammary fat pad, particularly the fourth mammary fat pad for a mouse, the popliteal ~`
fossa, or other convenient site where the organ may ~ ;~
be vascularized, lymphatic vessels connected and ; ;
maintained by the host for a reasonable period of time, usually at least four weeks, preferably at ~-least six weeks. Thus, the non-human mammal may `
provide ~or a significant portion of the human hematopoietic system with the continued regeneration of stem cells and generation of more than fifty -percent (50%) of the different types of committed or mature cells. In this manner cells of the .~ myelomonocytic lineage, such as macrophages, mast cells, neutrophils-~PMNs), eosinophils, basophils, --monocytes, megakaryocytes, etc. or the lymphoid -lineage, B lymphocytes, T lymphocytes, NX cells, ADCC cells, LAK cells, TIL cells, etc. may be - propagated, studied or used for various purposes. ~ ~
~ ' .
WO91/18fil~ ~?~3~5 PCT/US91/03306 The subject host may find a wide variety of uses by virtue of the significant presence of circulating human blood cells in the non-human host - ;
The host may be employed for the production of human monoclonal antibodies or immortalized T lymphocytes.
The host may be immunized in accordance with i conventional ways with an appropriate immunoqen, which may be injected intravascularly at an appropriate site. Of particular interest is iniection at a site which is drained by a human lymph node introduced into the host. The immunized host may receive one or more booster shots, followed by removal of a lymphoid organ, e.g. lymph node, ~ `
followed by immortalization, conveniently by fusion ;
with an appropriate myeloid cell or transfection with Epstein-Barr virus. Alternatively, the cells may be cloned by any convenient means, at li~iting dilution to provide for individual clones, and the supernatants of the individual clones may be screened for the binding affinity of the antibodies J ',~ "
present in the host. ~ ;
Alternatively, the host may be used for ;
studying T and B lymphocyte interactions, in ;
detarmining the manner of stimulation of T and B
lymphocyte~s and the mechanism for the immune reaction. Individual lymphocytes may be cloned to evaluate their role in disease protection against disease, identify sIg or T cell receptor variable regions, isolate the DNA encoding the variable regions, or the like. Various immunogens may be screened for their abilities as vaccinesi:in producing;antlbodies which may-be effective in neutralizing pathogens and-the cells or DNA provide a source of the variable regions associated with the ;
response. -Pathogens of interest are those particularly ~-WO9l/18615 PCT/US91/03306_ S ~. .
8 ~' associated with humans, such as HIV, HTLV-I, and - ~
II, human papilloma virus, cytomegalovirus, Epstein- -' Barr virus, hepatitis B virus, non-A, non-B - ' hepatitis, chlamydia, malaria (Falciparum) etc. ' Also, the subject system may be used in the study of - -' 'cancer in attempting to develop cytotoxic cells ' specific for a particular cancer type. - ' The following examples are offered by way of ''~' illustration and not by way of limitation. ;~ .
EXPERIMENTAL
Bone pieces were transplanted into either -~ -untreated mice (6-10 weeks old) or mice (6-10 weeks ~ -' old) pre-treated with radiation from a cesium 137 source. The mice are treated with either whole body irradiation or irradiation of the long bones. Nice treated with whole body irradiation receive 200 to '-400 rads on a single dose. Alternatively, the mice are treated with 600 rads after shielding of the thorax and abdomen with a lead shield. The mice are -anesthetized with Nembutol prior to shielded irradiation. The mice were C8-17.5 scid!scid mice.
In addition, some of the mice were treated with exogenous human IL-3 in two l~g doses per day. The ~ `
fetal bone pieces are prepared from fetuses of 18-22 week gestation by first removing all of the soft tissues and cartilagenous portions from the bone. '~
The bones are then cross sectioned at 2 -'5 mm ' l '~
intervals. The mice are prepared by in~ection ip of Nembutol.-'Once-the mice are fully ànesthetized, a 1 -'' cm incision'is'`madë in the skin as'wèll as the ' underlying peritoneum. The bone fragments are then - placed~into the peritoneal cavity randomly.
Approximately 25mm to l.5cm of a femur, tibia or humerus is implanted into each mouse. The mice ~ ~ .
W091/18615 ~ ~$ PCr/us9l/03~6 which are irradiated are irradiated within 24 hours of the subsequent implantation of the fetal bone.
After two to six weeks, the percentage of human cells in the peripheral blood is determined by employing monoclonal antibodies specific for human hematopoietic cell markers. In un-irradiated mice a low level of human cells is observed in the peripheral blood by FACScan. The positive cells vary from about O - l.6 percent. Furthermore, injection of IL-3 does not significantly affect the percentage of positive cells. In contrast, the mice irradiated before marrow transplantation showed between l.5 and 30 percent human cells in the peripheral blood. These cells appear to be of the myelomonocytic lineage. They show no staining with ~;
T or B cell markers (CD 3, 4, 8, l9), although they do stain for the myeloid cell marker (CD33). ;
Furthermore, the human cells have a high side scatter profile indicating that they are of the myelomonocytic lineage. In addition, two of the ~our mice which were irradiated before implantation show low but significant levels of serum immunoglobulin after six weeks.
The above results demonstrate that one can obtain high levels of human cells in an immunocompromised mouse at least partially ablated of endogenous bone marrow, by implanting relatively large amounts of human bone marrow, particularly with the stromal bone tissue. The human bone marrow ~-implanted after irradiation provides a mouse which results in substantial numbers of cells of hùman myelomonocytic~lineage and can provide for cells of other lineages as well, such as lymphoid. By ~ -appropriate combinations of tissue in conjunction with the bone marrow one can provide inside the immunocompromised mouse a hematopoietic system WO91/1~61S PCT/US91/03306 2~ S
,, mimicXing the human hematopoietic system. Thus, one may study various processes, compounds, drugs, or the like, and their effect on the human hematopoietic system by cytologic or histologic 5 analysis, selection, staining, or the like.
All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporaited by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Although the foregoing invention has been ;~-described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and ~-modi~ications may be practiced within the scope of the appended claims.
~; .
, . . . , ;., ~:
- - : ' ' ' ,,. :
'' ~', .
" .",~ :,"
IN AN IMMUNOCONPROMISED HOST
INTRODUCTION
Technical Field The field of this invention is the production of human hematopoietic cells.
Background The blood cell system comprising the diverse cells emanating from a single stem cell is essential to the survival and well being of mammals. The cells serve to carry oxygen, cleanse the body of debris, inhibit the proliferation of pathogens, monitor for neoplastic cells, and provide a wide variety of factors essential for their own and the growth of other cells. Recently, chimeric mice were developed, where human fetal tissue was introduced into CB-17 s d/scid mice to provide the chimeric SCID-hu mouse. The mice were shown to maintain for extended periods of time, human fetal lymph node and thymus and provide for peripheral blood cells, when supplied with a source of hematopoietic stem cells -from fetal liver. While in some instances, the maintenance of human peripheral blood cells could be extended for long periods of time, in all instances `~
.
the human cells were only a very small proportion of the total number of peripheral blood cells, `-. ,,, ~, . ...... .... . . ........ ........ ... .
frequently substantially fewer~than one percent.
Furthermore, the circulating cells in these animals were shown to be T Cells.
In many instances, it would be desirable to `
have a relatively high proportion of the peripheral blood cells as human cells and desirably have a . . . . .
WO91/186l5 PCT/US91/03306 2~ '5 -`
significant proportion of the total number of hematopoietic cells being human cells. Further, it would be desirable to have circulatory myelomonocytic cells and red blood cells, besides lymphoid cells.
For many applications, it would be of substantial advantage to have a high absolute number of human cells. These include the opportunity for immunization to obtain a strong immune response from the h~man cells, studies of various diseases and their effect on the various hematopoietic cells and studies of drugs against various diseases and their effect on the hematopoietic cells. There is, therefore, substantial interest in providing for ways in which a non-human mammal may be provided with human blood cells for testing, research, and as a source of blood cells of the various lineages.
. ~ ; , Relevant Literature EPA 0 322 240 describes the introduction of ~
human ~etal tissue in a C~-17 scid/scid mouse. See ~ ;
references cited therein.
` .
SUMMARY OF THE INVENTION
Xenogeneic bone marrow is introduced into an endogenous bone marrow depleted genetically ;~;~
immunocompromised mammalian host, where the bone ~ ;
marrow may be present as bone tissue or dispersed j:
bone marrow, particularly from a fetal source. The fetal bone tissue may be conveniently introduced into the peritoneal cavity or the bone marrow may be injectèd into the long bone of~the immunocompromised host.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
Non-human mammals, particularly small mammals .
WO91/18615 2~ ~. 5 PCT/US91/03306 under 25kg, are provided having human peripheral blood cells present as at least two percent (2%) of the total peripheral blood cells, preferably at least five percent (5%) of the total peripheral blood cells and more preferably at least about fifteen percent (15%). The enhanced level of human cells may be achieved by depletion of endogenous bone marrow, particularly stem cells, conveniently by irradiating the host with at least a sublethal dosage of radiation, generally being at least about 290 rad and varying with the size and nature of the host. The blood cells are then reconstituted with human bone marrow, conveniently as human bone or bone marrow cell suspensions, particularly from a ~ ;
fetal source. The human bone marrow source may be ~-introduced before and after ablation to enhance the survival rate of the host upon ablation, ; , particularly by irradiation.
Various immunocompromised hosts may be employed, where the host being immunocompromised is as a result of a natural mutation, breeding, transformation of embryonic cells to provide a transgenia mouse, or the like. Of particular interest are hosts which lack a functional lymphoid ;
~5 lineage. The lack of the immune system may be as a result of a lack of a particular organ, a genetic defect, such as an incompetent recombinase or regulatory gene regulating the expression of the recombinase, transport of sIg and T cell receptors to the surface, non-functional major - -histocompatibility antigensj or the like.- Of particular interest are CB-17 scid/scid mice and - mice derived therefrom which may have further enhanced immunodeficiency, e.g. lack of natural ~ ;
killer (NK) cells.
The host is irradiated or treated in any ' . ~ .
WO91/18615 2~ ~5 ~CT/US91/03306 convenient manner to substantially ablate the endogenous bone marrow. Conveniently, X-ir~adiation may be employed where the level of radiation will be selected to provide at least substantially complete ahlation of the hematopoietic cell system, while maintaining a reasonable, preferably a highl .
proportion of viable hosts. With each type of host, the particular level of irradiation may be selected by screening for the level of remaining viable hematopoietic cells for the efficiency of the ablation. Other techniques for bone marrow ablation -~
which may be employed by themselves or in combination include cytotoxic drugs, immunotoxins, antibodies to lymphokines and growth factors, ;:.
antibodies to natural killer cells, etc. The ;
selection of cytotoxic drugs would be based on their ability to clear quickly from the lymphatic and blood circulatory systems, so as to.rapidly be reduced to a non-cytotoxic level, prior to or .
shortly after the administration of the human bone :~.
marrow. :~
The human bone marrow will normally be fetal ;
bone marrow and may be employed as bone marrow slices, fragments, chunks, or the like, coming from ..
various parts of the fetus, such as the femur, tibia, humerus or rib. The longest dimensions of human bone will generally be in the size range of about 8mm to 2cm, where the bone may be fragmented :. :.
along.the long axis, usually in not more than about ,~
four parts. Usually, the total volume of fetal.bone .
which is;introduced into the-host will vary with the ~:
.- size of the host. For mice, the.volume will : generally be in the range of about ~Omm3 to 1,200mm3.
Alternatively, human fetal bone marrow cell ~ .
suspensions may be injected into long bones, such as the femur or tibia. Generally the volume of the - , ::: : -WO91/18615 ~ ~5 ` PCT/US91/03306 bone marrow suspension will be in the range of about lOml to 50ml for a mouse.
The age of the host will generally he at least neonatal and usually not more than about six months, more usually not more than three months. The particular age is not critical to this invention, but younger animals are more convenient to handle and are more economical.
The site of introduction of the fetal bone portions may be interperitoneal, subcutaneous, mammary fat pad, or other convenient site.
After introduction of the bone marrow, the host -is grown in accordance with conventional ways, `
feeding the host as appropriate, either with or without the presence of antibiotics in the feed.
Conveniently, about 0.2% to 1.2% of sulfamethoxazole/trimethoprim (Septra) may be provided in the feed. As appropriate, additional introductions of the human fetal bone marrow may be made, usually not more than about two additional explants, generally at four to twenty week intervals.
The hos~ may receive a variety of growth factors and cytokines, either native to the host or human. Interleukins, colony stimulating factors, hormones, or the like may be added, such as IL-l, IL-3, IL-6, and G-CSF. Generally, the amount of the additive will vary, depending upon the particular additive, the host, and the like. For example, in the case of IL-3 0.5 - 5 ~g/day may be administered.
In the subject host, it is found that the bone :- tissue shows variable cellularity from~lO to 80%.
In addition,-the human cells comprise a significant proportion of the blood cells in circulation in the peripheral blood. The cells may include members of the lymphoid, myelomonocytic and erythroid lineages.
WO91~1861S ~ ~ S PCT/US91/~3306 The cells may be detected by employing a wide varlety of antibodies which are commercially available for the detection of human markers on blood cells, such as CD-3, -4, -8, -l0, -13, -15, -19, -20, -33, -41, -45, -59, ~LA, or the like.
Conveniently, a blood sample may be taken and assayed employing a fluorescence activated cell ;~
sorter. Alternatively, the cells may be lysed and a Western blot employed. Other techniques which may ~ -find use for the quantitative determination of a ~ ~-particular cell type include the polymerase chain -~
reaction, gel electrophoresis, HPLC, or the like.
In addition to the bone marrow, other human organs may also be present, particularly thymus, lymph node, skin, liver, pancreas, tonsil, appendix, -epithelium, kidney, etc. One or more mesenteric or peripheral lymph nodes may be introduced. The various organs may be introduced conveniently in the kidney capsule, mammary fat pad, particularly the fourth mammary fat pad for a mouse, the popliteal ~`
fossa, or other convenient site where the organ may ~ ;~
be vascularized, lymphatic vessels connected and ; ;
maintained by the host for a reasonable period of time, usually at least four weeks, preferably at ~-least six weeks. Thus, the non-human mammal may `
provide ~or a significant portion of the human hematopoietic system with the continued regeneration of stem cells and generation of more than fifty -percent (50%) of the different types of committed or mature cells. In this manner cells of the .~ myelomonocytic lineage, such as macrophages, mast cells, neutrophils-~PMNs), eosinophils, basophils, --monocytes, megakaryocytes, etc. or the lymphoid -lineage, B lymphocytes, T lymphocytes, NX cells, ADCC cells, LAK cells, TIL cells, etc. may be - propagated, studied or used for various purposes. ~ ~
~ ' .
WO91/18fil~ ~?~3~5 PCT/US91/03306 The subject host may find a wide variety of uses by virtue of the significant presence of circulating human blood cells in the non-human host - ;
The host may be employed for the production of human monoclonal antibodies or immortalized T lymphocytes.
The host may be immunized in accordance with i conventional ways with an appropriate immunoqen, which may be injected intravascularly at an appropriate site. Of particular interest is iniection at a site which is drained by a human lymph node introduced into the host. The immunized host may receive one or more booster shots, followed by removal of a lymphoid organ, e.g. lymph node, ~ `
followed by immortalization, conveniently by fusion ;
with an appropriate myeloid cell or transfection with Epstein-Barr virus. Alternatively, the cells may be cloned by any convenient means, at li~iting dilution to provide for individual clones, and the supernatants of the individual clones may be screened for the binding affinity of the antibodies J ',~ "
present in the host. ~ ;
Alternatively, the host may be used for ;
studying T and B lymphocyte interactions, in ;
detarmining the manner of stimulation of T and B
lymphocyte~s and the mechanism for the immune reaction. Individual lymphocytes may be cloned to evaluate their role in disease protection against disease, identify sIg or T cell receptor variable regions, isolate the DNA encoding the variable regions, or the like. Various immunogens may be screened for their abilities as vaccinesi:in producing;antlbodies which may-be effective in neutralizing pathogens and-the cells or DNA provide a source of the variable regions associated with the ;
response. -Pathogens of interest are those particularly ~-WO9l/18615 PCT/US91/03306_ S ~. .
8 ~' associated with humans, such as HIV, HTLV-I, and - ~
II, human papilloma virus, cytomegalovirus, Epstein- -' Barr virus, hepatitis B virus, non-A, non-B - ' hepatitis, chlamydia, malaria (Falciparum) etc. ' Also, the subject system may be used in the study of - -' 'cancer in attempting to develop cytotoxic cells ' specific for a particular cancer type. - ' The following examples are offered by way of ''~' illustration and not by way of limitation. ;~ .
EXPERIMENTAL
Bone pieces were transplanted into either -~ -untreated mice (6-10 weeks old) or mice (6-10 weeks ~ -' old) pre-treated with radiation from a cesium 137 source. The mice are treated with either whole body irradiation or irradiation of the long bones. Nice treated with whole body irradiation receive 200 to '-400 rads on a single dose. Alternatively, the mice are treated with 600 rads after shielding of the thorax and abdomen with a lead shield. The mice are -anesthetized with Nembutol prior to shielded irradiation. The mice were C8-17.5 scid!scid mice.
In addition, some of the mice were treated with exogenous human IL-3 in two l~g doses per day. The ~ `
fetal bone pieces are prepared from fetuses of 18-22 week gestation by first removing all of the soft tissues and cartilagenous portions from the bone. '~
The bones are then cross sectioned at 2 -'5 mm ' l '~
intervals. The mice are prepared by in~ection ip of Nembutol.-'Once-the mice are fully ànesthetized, a 1 -'' cm incision'is'`madë in the skin as'wèll as the ' underlying peritoneum. The bone fragments are then - placed~into the peritoneal cavity randomly.
Approximately 25mm to l.5cm of a femur, tibia or humerus is implanted into each mouse. The mice ~ ~ .
W091/18615 ~ ~$ PCr/us9l/03~6 which are irradiated are irradiated within 24 hours of the subsequent implantation of the fetal bone.
After two to six weeks, the percentage of human cells in the peripheral blood is determined by employing monoclonal antibodies specific for human hematopoietic cell markers. In un-irradiated mice a low level of human cells is observed in the peripheral blood by FACScan. The positive cells vary from about O - l.6 percent. Furthermore, injection of IL-3 does not significantly affect the percentage of positive cells. In contrast, the mice irradiated before marrow transplantation showed between l.5 and 30 percent human cells in the peripheral blood. These cells appear to be of the myelomonocytic lineage. They show no staining with ~;
T or B cell markers (CD 3, 4, 8, l9), although they do stain for the myeloid cell marker (CD33). ;
Furthermore, the human cells have a high side scatter profile indicating that they are of the myelomonocytic lineage. In addition, two of the ~our mice which were irradiated before implantation show low but significant levels of serum immunoglobulin after six weeks.
The above results demonstrate that one can obtain high levels of human cells in an immunocompromised mouse at least partially ablated of endogenous bone marrow, by implanting relatively large amounts of human bone marrow, particularly with the stromal bone tissue. The human bone marrow ~-implanted after irradiation provides a mouse which results in substantial numbers of cells of hùman myelomonocytic~lineage and can provide for cells of other lineages as well, such as lymphoid. By ~ -appropriate combinations of tissue in conjunction with the bone marrow one can provide inside the immunocompromised mouse a hematopoietic system WO91/1~61S PCT/US91/03306 2~ S
,, mimicXing the human hematopoietic system. Thus, one may study various processes, compounds, drugs, or the like, and their effect on the human hematopoietic system by cytologic or histologic 5 analysis, selection, staining, or the like.
All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporaited by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Although the foregoing invention has been ;~-described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and ~-modi~ications may be practiced within the scope of the appended claims.
~; .
, . . . , ;., ~:
- - : ' ' ' ,,. :
'' ~', .
" .",~ :,"
Claims (13)
1. A non-primate genetically immunocompromised mammalian host comprising at least two percent circulating human blood cells of the total number of circulating blood cells in the blood stream of said host, said host being produced by substantially ablating endogenous bone marrow and implanting human bone marrow.
2. A non-primate host according to Claim 1, wherein said ablating is by at least sublethal irradiation.
3. A non-primate host according to Claim 1, wherein said human bone marrow is bone tissue.
4. A non-primate host according to Claim 1, wherein said human bone marrow is dispersed bone marrow.
5. A non-primate host according to Claim 1, wherein said host is murine.
6. A murine genetically immunocompromised host, wherein said host lacks functional B and T
lymphocytes as a result of a genetic defect, said host comprising at least five percent circulating human blood cells of the total number of circulating blood cells in the blood stream of said host, said host being produced by substantially ablating endogenous bone marrow and implanting human bone marrow.
lymphocytes as a result of a genetic defect, said host comprising at least five percent circulating human blood cells of the total number of circulating blood cells in the blood stream of said host, said host being produced by substantially ablating endogenous bone marrow and implanting human bone marrow.
7. A murine host according to Claim 6, wherein said host is a CB-17 scid/scid mouse or progeny thereof.
8. A murine host according to Claim 7, comprising at least twenty-five percent of circulating human blood cells.
9. A murine host according to Claim 6, comprising human fetal bone marrow.
10. A murine host according to Claim 6, comprising at least one of human lymph node, liver or thymus tissue.
11. A murine host according to Claim 6, wherein said host is at least six weeks old from the time of implantation of said human bone marrow.
12. A murine host according to Claim 6 comprising circulating human immunoglobulins.
13. A murine host according to Claim 6, wherein said murine host is irradiated with at least 200 rad.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52921790A | 1990-05-25 | 1990-05-25 | |
US529,217 | 1990-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2064075A1 true CA2064075A1 (en) | 1991-11-26 |
Family
ID=24108994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002064075A Abandoned CA2064075A1 (en) | 1990-05-25 | 1991-05-13 | Human peripheral blood cells in an immunocompromised host |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0484512A4 (en) |
JP (1) | JPH05500617A (en) |
CA (1) | CA2064075A1 (en) |
WO (1) | WO1991018615A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652373A (en) * | 1990-01-15 | 1997-07-29 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
US5849288A (en) * | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
ES2090332T3 (en) * | 1990-05-03 | 1996-10-16 | Systemix Inc | HUMAN LYMPHOID TISSUE IN AN IMMUNOCOMMITTED HOSPITAL. |
US5858328A (en) * | 1991-06-04 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Animal model for hepatitis virus infection |
US5849987A (en) * | 1992-06-02 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Animal model for hepatitis virus infection |
US5804160A (en) * | 1991-06-04 | 1998-09-08 | Yeda Research And Development Co. Ltd | Animal model for hepatitis virus infection |
DE69229254T2 (en) * | 1991-10-30 | 1999-09-23 | Idemitsu Kosan Co | Processes for the production of human lymphocytes and human antibodies; and antibodies so produced |
US6353150B1 (en) * | 1991-11-22 | 2002-03-05 | Hsc Research And Development Limited Partnership | Chimeric mammals with human hematopoietic cells |
US5866757A (en) * | 1992-06-02 | 1999-02-02 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
EP0659046A1 (en) * | 1992-09-11 | 1995-06-28 | The Regents of The University of Michigan | Non-human animal with xenograft of on airway populated by human cells |
JP4236279B2 (en) * | 1993-05-24 | 2009-03-11 | ズィメレックス・インコーポレーテッド | Surrogate tolerance formation for the development of tolerance to xenotransplantation |
US8541646B2 (en) | 2009-10-06 | 2013-09-24 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
RU2577978C2 (en) | 2011-02-15 | 2016-03-20 | Ридженерон Фармасьютикалз, Инк. | Humanised mouse m-csf |
KR102594390B1 (en) | 2012-09-07 | 2023-10-27 | 예일 유니버시티 | Genetically modified non-human animals and methods of use thereof |
EP4389764A2 (en) | 2012-11-05 | 2024-06-26 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
KR102627332B1 (en) | 2014-05-19 | 2024-01-26 | 리제너론 파마슈티칼스 인코포레이티드 | Genetically modified non-human animals expressing human epo |
PT3282835T (en) | 2015-04-13 | 2023-07-25 | Univ Yale | Humanized sirpa-il15 knockin mice and methods of use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0322240B1 (en) * | 1987-12-23 | 1995-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric immunocompromised mammals and their use |
JP2981486B2 (en) * | 1988-06-14 | 1999-11-22 | メディカル・バイオロジー・インスティチュート | Mammalian immune system research methods |
-
1991
- 1991-05-13 CA CA002064075A patent/CA2064075A1/en not_active Abandoned
- 1991-05-13 WO PCT/US1991/003306 patent/WO1991018615A1/en not_active Application Discontinuation
- 1991-05-13 JP JP3510612A patent/JPH05500617A/en active Pending
- 1991-05-13 EP EP19910911224 patent/EP0484512A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JPH05500617A (en) | 1993-02-12 |
WO1991018615A1 (en) | 1991-12-12 |
EP0484512A4 (en) | 1993-05-05 |
EP0484512A1 (en) | 1992-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2064075A1 (en) | Human peripheral blood cells in an immunocompromised host | |
Mueller et al. | Potential of the scid mouse as a host for human tumors | |
Daley et al. | Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome | |
Kwon et al. | Immune responses in 4-1BB (CD137)-deficient mice | |
Metcalf et al. | Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. | |
DE69233163T3 (en) | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T lymphocytes. | |
Martinov et al. | Building the next generation of humanized hemato-lymphoid system mice | |
DE60131676T2 (en) | PROCESS FOR MAKING A MOUSE SUITABLE FOR THE RECORDING, DIFFERENTIATION AND PROLIFERATION OF HETEROGENIC CELLS, THE MOUSE PRODUCED THEREOF AND THEIR USE | |
Naito et al. | Severe osteopetrosis, defective interleukin‐1 signalling and lymph node organogenesis in TRAF6‐deficient mice | |
Nacht et al. | Mutations in the p53 and SCID genes cooperate in tumorigenesis. | |
US5633426A (en) | In vivo use of human bone marrow for investigation and production | |
US20120251528A1 (en) | Non-Human Mammal Model Of Human Hematopoietic Cancer | |
JP2012531896A (en) | Method for producing a humanized non-human mammal | |
AU2005322907A2 (en) | Facilitated cellular reconstitution of organs and tissues | |
Drize et al. | Long-term maintenance of hematopoiesis in irradiated mice by retrovirally transduced peripheral blood stem cells | |
JP4906059B2 (en) | Screening method for human platelet number regulator | |
ES2211876T3 (en) | DETECTION AND TREATMENT OF MUTATIONS IN A LEAGUE OF CD40 GEL. | |
Van Etten | Models of chronic myeloid leukemia | |
Li et al. | A novel animal model for bone metastasis in human lung cancer | |
Rolstad et al. | The “natural resistance” to bone marrow allografts in normal and athymic nude rats Rapid cytotoxic reactions both in vivo and in vitro | |
Borzillo et al. | Early pre-B-cell transformation induced by the v-fms oncogene in long-term mouse bone marrow cultures | |
Puig et al. | Myeloablation enhances engraftment of transduced murine hematopoietic cells, but does not influence long-term expression of the transgene | |
Ende et al. | The effect of human cord blood on SJL/J mice after chemoablation and irradiation and its possible clinical significance | |
Wermann et al. | Human-mouse xenografts in stem cell research | |
JP4245332B2 (en) | Animal model of human multiple myeloma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |